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Morphologic studies have indicated that Langerhans 
cells (LC) are frequendy in anatomic apposition with 
epidennal nerves containing the neuropeptide calci­
tonin gene-related peptide (CGRP). Experiments 
were undertaken to examine whether CGRP modu­
lates LC function. The effect of pre-exposure of LC to 
CGRP in vitro on alloantigen presentation and spe­
cific protein presentation to a responsive T-cell line 
were studied using freshly prepared murine epider­
mal cell populations enriched for LC content (EC) by 
treatment with antibody to Thy-l and complement. 
The ability of EC to present tumor-associated anti­
gens for induction and elicitation of delayed-type 
hypersensitivity (DTH) in tumor-immune mice was 
also examined. Inhibitory effects of CGRP on antigen 
presentation were observed in each of these assays. 
Experiments were also perfonned examining the 
ability of intradennally administered CGRP to mod-
S everal lines of evidence suggest an interaction between the cutaneous immune system and the nervous system (Reichlin, 1993). Some skin disorders, including psori­asis and atopic dermatitis, reportedly exacerbate with stress during periods of anxiety and have been associated 
with abnormal local neuropeptide expression (Anand et ai, 1991). 
Furthermore, the thymus, lymph nodes, and spleen are innervated 
(Walker and Codd, 1985; Felten et ai, 1987; Stead et ai, 1987; 
Lorton et ai, 1991). Langerhans cells are dendritic antigen-present­
ing cells (APC) that presumably function to present encountered 
antigens for induction and elicitation of immunity (Stingl et ai, 
1977; Romani et ai, 1989; Kapsenberg and Teunissen, 1990). 
Langerhans cells have been shown in many assay systems to be 
capable of presenting hap tens and immunogenic proteins for cell­
mediated immune responses (Stingl et ai, 1977; Romani et ai, 1989; 
Kapsenberg and Teunissen, 1990). Calcitonin gene-related peptide 
(CGRP) is a 37-amino acid neuropeptide that is widely expressed in 
both the central and peripheral nervous system. It is a product of an 
alternate splicing of the calcitonin gene transcript (Brain et ai, 
1985). CGRP and substance P are known as pro-inflammatory 
factors that are thought to be involved in neurogenic inflammation. 
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Abbreviations: APC, antigen-presenting cells; CGRP, calcitonin gene­
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CHS, contact hypersensitivity. 
ulate induction of contact hypersensitivity (CHS) to a 
hapten applied at the injected site. Administration of 
CGRP led to a decrease in the CHS response after 
immunization at the site of injection. Intracellular 
cAMP was significandy increased in freshly prepared 
LC after exposure to CGRP, and this process could be 
inhibited by a specific inhibitor of the CGRP recep­
tor, demonstating the existence of CGRP receptors 
on LC. B7-2 expression induced by LPS and GM-CSF 
in the LC-like line XS52, and by LPS in peritoneal 
macrophages, was suppressed by CGRP. This sup­
pression may account, in part, for the inhibitory 
effect of CGRP. As a whole, these observations sug­
gest that regulation of antigen presentation by nerves 
may occur in the epidennis. Key words: neuropeptidel 
CGRPILangerhans cells. Journal of Investigative Dermatol­
ogy Symposium Proceedings 2:82-86, 1997 
Intradermal injection of CGRP induces microvascular dilatation 
resulting in increased blood flow and persistent local reddening 
(Brain et ai, 1985). A significant increase in the CGRP content of 
dorsal root ganglia was found in adjuvant monoarthritis in the rat 
(Smith et ai, 1992). CGRP is reported to stimulate the adhesiveness 
of human umbilical vein endothelial cells for monocytic cell line 
and neutrophils in a dose- and time-dependent mauner (Sung et aI, 
1992). Furthermore, CGRP has potentiating e/fects on neutrophil 
accumulation and edema formation induced by intradermal injec­
tion of several inflammatory mediators including interleukin-1 
(IL-1) (Buckley et ai, 1991). On the other hand, anti-inflammatory 
e/fects of CGRP have been reported in some systems. CGRP was 
found to inhibit edema-promoting actions of inflammatory media­
tors (histamine, leukotriene B4, 5-hydroxytryptamine) in vivo in the 
hamster cheek pouch, human skin, and rat paw (Raud et ai, 1991). 
Local administration of CGRP decreased inflammation in the 
mouse ear induced by croton oil, arachidonic acid, or tetradeca­
noylphorbol acetate (Clementi et ai, 1994). 
The pro-inflammatory and anti-inflammatory e/fects of CGRP 
described above were in systems not involving antigen-specific 
immunity. Several neuropeptides and neurohormones a/fect various 
aspects of macrophage and lymphocyte function (Weihe and 
Hartschuh, 1988; Girolomoni and Tigelaar, 1990). CGRP inhibits 
the proliferative response of mouse spleen cells to mitogens 
(Umeda et ai, 1988), IL-2 production by T cells (Boudard and 
Bastide, 1991; Wang et ai, 1992), and, of particular interest, some 
macrophage functions including antigen-presenting capacity (Nong 
et ai, 1989). The e/fects of CGRP on the antigen-presenting 
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capabilities of Langerhans cells were investigated in both a1ferent 
and efferent pathways of the immune response, and the possible 
mechanisms of this effect were studied in several aspects. This 
review will summarize the results of these studies. 
FUNCTIONAL ANALYSES 
In vitro, mixed in vitro/in vivo, and wholly in vivo functional assays 
were performed to study the putative regulatory activities of 
CGRP. Alloantigen presentation and specific protein presentation 
to a responsive T -T hybridoma were investigated after exposure of 
epidermal APC to CGRP in vitro. The ability of CGRP to regulate 
the capacity of epidermal APC to present soluble tumor-associated 
antigens (TAA) for induction or elicitation of immunity in vivo was 
also examined. To examine the ability of CGRP to regulate 
immune functions in the skin in vivo, a model of induction of 
immunity to a hapten painted epicutaneously at the site of intrad­
ermal injection of CGRP was utilized. 
In Vitro Assays 
Alloantigen Presentation We examined the effect of CGRP on 
alloantigen presentation by freshly prepared murine epidermal cell 
populations to allogenic T lymphocytes in the mixed epidermal 
cell/lymphocyte reaction (Aberer et aI, 1982). Pre-treatment of 
BALB/c (H_2d) epidermal cells with 10 nM or 100 nM CGRP 
inhibited the ability of epidermal cells to stimulate the proliferation 
of T cells from C3H/He] (H_2k) mice (Hosoi et aI, 1993). When 
responding T cells were treated with CGRP, instead of epidermal 
cells, no effect was observed. These results indicated that CGRP 
inhibited antigen presentation by epidermal cells and suggested that 
the locus of action of CGRP resided in stimulating cells. Deletion 
of I-A + cells by antibody and complement-mediated lysis abrogated 
the ability of epidermal cells to stimulate lymphocyte proliferation 
in this assay. Thus, it was concluded that Langerhans cells were 
responsible for the allostimulation observed. 
Specific Protein Presentation to a Responsive T-T Hybridoma The 
ability of CGRP to inhibit epidermal cell antigen presentation was 
also examined using the response of a T-T hybridoma (D011.1) to 
presentation of chicken ovalbumin presented by I_Ad. This line 
produces IL-2 in response to presentation of the appropriate antigen 
(Shimonkevitz et aI, 1984), and IL-2 production can be assessed by 
examining the ability of supernatants to support the proliferation of 
the IL-2-dependent cell line CTLL. CGRP also inhibited the ability 
of epidermal cells to present antigen in this assay (Hosoi et aI, 1993). 
It inhibited presentation of both the native protein and an immu­
nogenic peptide derived from chicken ovalbumin that is recognized 
by D011.1 cells without processing. Control peptides consisting of 
a truncated form of CGRP (CGRPS_37) that binds to the CGRP 
receptor but does not signal and substance P were inactive in this 
assay. 
Specific Protein Presentation to a Th 1 Clone It is now well known 
that two populations of helper T cells, Thl and Th2 cells, are 
recognized by cytokine secretion profiles, and Langerhans cells 
have been shown to present antigen to both Thl and Th2 cells (Enk 
et aI, 1993). To investigate the effect of CGRP on epidermal cell 
antigen presentation to Thl cells, the pigeon cytochrome c-specific, 
I-Ek-restricted Thl clone A.E7 was used (Mueller et aI, 1994). 
Epidermal cells from A/] mice were pre-incubated in medium alone 
or 100 nM CGRP with the addition of pigeon cytochrome c for the 
last 3.5 h. Mter incubation, these cells were washed and mixed with 
A.E7 cells in medium containing indomethacin. Cells were cultured 
for 72 h and evaluated for proliferative activity by the assessment of 
[3H]thymidine incorporation. Treatment with CGRP significandy 
inhibited epidermal cell presentation of pigeon cytochrome c to 
A.E7 (Asahina et al, 1995b). This inhibition of the antigen­
presenting capability of epidermal cells by CGRP could be com­
pletely blocked by CGRPS_37 added at 100-fold excess. 
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Figure 1. CGRP inhibits epidermal cell antigen presentation for 
the induction phase of DTH. CAF1 epidermal cells were incubated in 
medium containing 50 U GM-CSF per ml with or without 100 nM CGRP 
prior to exposure to TAA. Negative control mice were injected with 
epidermal cells not exposed to TAA. After extensive w�hing, the epider­
mal cells were injected s.c. into naive CAFt mice on the lower back three 
times at weekly intervals. One week after the last immunization, recipient 
mice were challenged by s.c. injection of TAA-pulsed epidermal cell 
suspensions into the left hind footpad. Twenty four-hour footpad swelling 
was assessed as a measure of DTH response. Positive control versus 100 nM 
CGRP, P = 0.009. Error bars, SEM. 
Mixed In Vitro/In Vivo Assays 
Induction oj Delayed-Type Hypersensitivity Experiments were de­
signed that would examine the effect of in vitro CGRP treatment on 
epidermal cell antigen presentation in a system utilizing an in vivo 
read-out method. CAFt (H_2a/d) epidermal cells were incubated 
concurrendy in medium containing 100 nM CGRP and 50 U 
murine granulocyte-macrophage colony-stimulating factor (GM­
CSF) per mI. Exposure of epidermal cells to GM-CSF has previ­
ously been shown to be required for epidermal cells to become 
competent to present TAA for induction of in vivo anti-tumor 
immunity (Grabbe et aI, 1992). After incubation, the cells were 
washed and pulsed with TAA derived from the S1509a spindle cell 
tumor (H-2a). The epidermal cells were then washed to remove 
unbound TAA and injected subcutaneously (s.c.) into naive CAFt 
mice on the lower' back. This protocol was repeated at weekly 
intervals for a total of three immunizations. One week after the last 
immunization, recipient mice were challenged by s.c. injection of 
TAA-pulsed epidermal cell suspensions into the left hind footpad. 
Footpad swelling was measured 24 h later as a measure of delayed­
type hypersensitivity (DTH). The positive control group, for which 
epidermal cells were incubated in GM-CSF alone before pulsing 
with T AA, showed significant footpad swelling. Exposure of 
epidermal cells to CGRP along with GM-CSF, however, abrogated 
the ability of these cells to induce immunity, s�ggesting that CGRP 
inhibits the ability of Langer hans cells to effectively present T AA in 
this system (Asahina et aI, 1995a). An experiment demonstrating 
this effect is shown in Fig 1. CGRPs_37 failed to show significant 
inhibition in this assay. 
. 
Elicitation oj Delayed-Type Hypersensitivity Experiments were also 
carried out to examine the capacity of CGRP to modulate the 
epidermal cell presentation of T AA for the elicitation phase of the 
immune response. This was done by taking advantage of the ability 
of Langerhans cells to present TAA for elicitation of DTH after 
injection into the footpad of a previously immunized mouse. Naive 
CAFt truce were immunized three times at weekly intervals by s.c. 
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Figure. 2 CGRP inhibits epidermal cell antigen presentation for 
the elicitation phase of delayed-type hypersensitivity. Naive CAF1 
mice were immunized three times at weekly intervals by s.c. injection of 
disrupted S1509a cells. Those mice were challenged 1 wk after the last 
intmunization by injection into a hind footpad with CAF1 epidermal cells 
incubated for 2 h with 10 or 100 nM CGRP prior to exposure to TAA and 
washing. Negative control mice were challenged with epidermal cells not 
exposed to TAA. Twenty four-hour footpad swelling was assessed as a 
measure of DTH response. CGRP inhibited footpad swelling in a dose­
dependent manner. Positive control versus 10 nM CGRP, P = 0.024, 
Positive control versus 100 nM CGRP, P = 0.017. Error bars, SEM. 
injection of killed (freeze-thaw for four cycles) S1509a cells. Those 
mice were challenged 1 wk after the last immunization by injection 
into a hind footpad with CAF1 epidermal cells incubated for 2 h 
with varying concentrations of CGRP prior to exposure to T AA. 
Twenty-four hour footpad swelling was then assessed as a measure 
of DTH response. Pre-treatment with CGRP led to a dose­
dependent decrease in the ability of epidermal cells to elicit DTH in 
this system (Hosoi et ai, 1993; Asahina et ai, 1995b). An experiment 
demonstrating this effect is shown in Fig 2. Other experiments 
demonstrated that deletion of I-A + cells elirniIlated the ability of 
epidermal cells to elicit immunity in the system; thus Langerhans 
cells are responsible for antigen presentation. This inhibition did 
not seem to be due to carryover of CGRP into the host animal 
inasmuch as injection of a mixture of epidermal cells pulsed with 
antigen and epidermal cells not pulsed with antigen but pre­
incubated in CGRP allowed for a full DTH response. This mixing 
experiment also suggested that CGRP did not produce its effects 
indirectly by stimulating keratinocytes to produce an inhibitor that 
acts on Langerhans cells. To further rule out that possibility, an 
additional experiment was performed utilizing a fluorescence­
activated cell sorter-enriched Langerhans cells population in this 
assay. CGRP exposure also inhibited the ability of these cells to 
elicit DTH. Several control proteins including transforming growth 
factor-J3, tumor necrosis factor-a, and CGRP8_37 had no effect on 
antigen presentation in this assay. Thus, it can be concluded that 
CGRP can specifically suppress Langerhans cells function in the 
elicitation phase of DTH. 
In Vivo Assay 
InductiOlt of Contact Hypersensitivity To investigate further the 
possible immunomodulatory activity of endogenous CGRP in the 
skin, an in vivo assay was utilized in which the effect of intradermally 
administered CGRP on induction of contact hypersensitivity (CHS) 
could be examined. Five hundred-thirty picomoles of CGRP or 
diluent alone were injected intradermally into the dorsum of the left 
ear of naive mice 8 h and 3 h before epicutaneous application of 
lID SYMPOSIUM PROCEEDINGS 
trinitrochlorobenzene or dinitrofluorobenzene at the injected site. 
Mice were challenged with hapten on the right ear 7 d later, and 
24-h ear swelling was assessed. CGRP significantly inhibited the 
induction of CHS in the majority of experiments, and this inhibition 
of CHS induction was observed both with trinitrochlorobenzene 
and dinitrofluorobenzene (Asahina et ai, 1995a). The specificity of 
this effect was demonstrated by the failure of control peptides, such 
as substance P, calcitonin, and CGRP8_37, to show activity in this 
assay. Additional experiments were performed to examine whether 
the CGRP effect was local or systemic. CGRP was administered s.c. 
just caudal to the base of the ear 5 to 10 mm from the site of 
immunization using the same schedule as above. Subcutaneous 
administration was employed to minimize spread of CGRP through 
dermal lymphatics to the site of immunization. When hapten was 
applied at a site distant from CGRP administration, no inhibition of 
CHS was observed, suggesting that the effect of CGRP is local. 
This observation is consistent with the reports that systemic treat­
ment of rat or guinea pigs with capsaicin led to exaggerated DTH 
and CHS responses (Nilsson and Ahlstedt, 1989; Wallengren et ai, 
1991). It should be mentioned that a conflicting report is in the 
literature. Gutwald et al (1991) used topical application of 10 ILM 
substance P or 1 ILM CGRP and somatostatin to analyze the effects 
of neuropeptides on induction of CHS. In their report, groups of 
mice were treated for 4 d twice daily beginning 1 d prior to 
sensitization by painting 50 ILl of either SP, CGRP, or somatostatin 
solution on the shaved abdominal wall. Sensitization was carried 
out 30 min after neuropeptide application. Mice were challenged 
6 d later on the dorsal surface of both ears. In this model, CGRP 
treatment induced a significantly increased ear swelling whereas 
substance P and somatostatin application showed no change. The 
reason for the discordance in the results observed between these 
two systems is not clear, but the dose, route, and schedule of 
administration of CGRP differed greatly between these two sys­
tems. These factors may account for the different results observed. 
MORPHOLOGIC STUDIES 
Morphologic studies were carried out to examine the relationship 
of epidermal Langerhans cells to CGRP-containing nerves. Human 
skin was employed because human epidermis is much thicker than 
mouse epidermis, and evaluation of anatomic relationships is 
therefore less difficult. Double immunofluoresence staining was 
performed using rabbit anti-human CGRP antiserum and mouse 
anti-human CD1a staining. A laser confocal scanning imaging 
system was utilized to visualize the structures. A network of highly 
dendritic CD1 + Langerhans cells were observed to be distributed 
uniformly throughout the epidermis, and intimate associations of 
CDl + epidermal Langerhans cells with CGRP+ epidermal nerves 
were frequently found (Hosoi et ai, 1993). Nerves consistently 
appeared to terminate at Langerhans cell bodies whereas association 
with Langerhans cell dendrites was not observed. Of particular 
significance, occasional Langerhans cell bodies showed patchy 
reactivity for CGRP. This observation is consistent with deposition 
of CGRP onto cells by nearby axons. These morphologic observa­
tions provide a structural basis for the functional results described 
above. To confirm the association of epidermal nerves and Lang­
erhans cells at an ultrastructual level, transmission electron micros­
copy of normal human skin was performed. A Langerhans cell was 
visualized with a process containing axon-like structures directly 
impinging upon it. 
STUDIES ON MECHANISM(S) OF ACTION 
Studies were undertaken to elucidate the mechanism(s) of action of 
CGRP in inhibiting antigen presentation. First, an examination of 
CGRP-induced increases in Langerhans cell cAMP was performed 
to validate the presence of CGRP receptors on Langerhans cells. 
Experiments were also performed to examine the effect of CGRP 
on expression of the co-stimulatory molecule B7-2 and a possible 
regulatory effect of CGRP on cytokine expression by APC. 
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Induction of cAMP by CGRP Many neuropeptides and non­
peptide neurotransmitters transduce signals through specific G 
protein- coupled receptors. G proteins activate two major second­
messenger systems, the cAMP-protein kinase A pathway and the 
phosphatidylinositol-protein kinase C pathway. Several ion chan­
nels are also regulated by second-messenger systems coupled to G 
proteins. Stimulation of the CGRP activates adenylate cyclase, and 
increases in intracellular cAMP levels and! or adenylate cyclase 
activity occur after exposure of relevant target cells to CGRP. 
Therefore, measurement of intracellular cAMP after stimulation 
with CGRP was used to demonstrate an interaction between 
CGRP and putative CGRP receptors on Langerhans cells. Langer­
hans cells were isolated from murine epidermal cells with antibod­
ies linked to magnetic microspheres. Mter 10 min of 100 nM rat 
CGRP incubation, the level of cAMP in freshly isolated Langerhans 
cells was significantly elevated, whereas both unseparated epider­
mal cells and the negatively selected keratinocytes responded only 
modestly to CGRP (Asahina et aI, 1995b). Induction of intracellular 
cAMP with CGRP in Langerhans cells was dose-dependent and 
was inhibited by the CGRP antagonist CGRP 8-37' a truncated form 
of CGRP missing the first seven amino acids, which acts as a 
competitive inhibitor. Both CGRP-I and CGRP-ll, which differ at 
a single amino acid, were efficient at inducing cAMP in Langerhans 
cells. Interestingly, it was found that vasoactive intestinal polypep­
tide was as effective as CGRP at inducing cAMP accumulation in 
Langerhans cells, indicating that Langerhans cells also have recep­
tors for vasoactive intestinal polypeptide. 
Studies on B7 Expression In addition to the signal provided to 
the T cell by binding to MHC molecules containing an antigenic 
peptide, T-cell activation appears to require a second signal pro­
vided by an additional receptor-ligand interaction. CD28-B7 inter­
action has been found to serve as a co-stimulatory signal for T cell 
activation in both mice and humans. B7 has been shown to 
comprise a family of at least three distinct molecules termed B7-1, 
B7-2, and B7-3, and the expression B7-1 and B7-2 by Langerhans 
cells has been reported. 
To analyze B7-2 expression by Langerhans cells, we used a 
dendritic cell line (XS52) derived from neonatal BALB/ c epidermis 
that presents antigen and has many of the phenotypic characteristics 
of freshly harvested Langerhans cells (Xu et aI, 1995). XS52 cells 
were cultured without GM-CSF for 48 h. Then, they were cultured 
for 24 h in medium containing GM-CSF and lipopolysaccharide 
(LPS) in the presence or absence of CGRP-I. Flow cytometry 
showed induction ofB7-2 expression in XS52 cells with GM-CSF 
and LPS; however, this induction was suppressed by CGRP-I 
(Asahina et aI, 1995b). LPS-induced B7-2 expression in peritoneal 
macrophages was also suppressed by CGRP-I. This supression of 
B7-2 expression may be one of the mechanisms responsible for the 
inhibitory effect of CGRP on antigen presentation. Preliminary 
experiments examining the CGRP effects on upregulation ofB7-1 
expression by XS52 cells suggest that CGRP may have little or no 
effect on B7-1 expression. 
Cytokine Regulation To determine whether CGRP may pro­
duce some of its functional effects through regulation of immuno­
modulatory cytokine expression, expression of IL-10, IL-1�, and 
the 40-kDa subunit (P40) of IL-12 was investigated in the Langer­
hans cell-like cell line XS52 cells and peritoneal macrophage in a 
series of experiments. 
IL-10 was first recognized as a Th2 cell product that inhibited the 
proliferation of Th1 cell clones by downregulating INF'Y and IL-2 
production (Fiorentino et aI, 1989). This effect was shown to be 
dependent on the presence of viable APC. IL-1� is selectively 
expressed in Langerhans cells in the epidermis, and the expression 
of IL-1� has been found to increase in culture in concert with 
enhanced antigen-presenting capacity (Heufler et aI, 1992). IL-12 is 
a heterodimer of 70 kDa formed by two covalently linked glyco­
sylated chains of 40 kDa (P40) and 35 kDa (P35). It was originally 
described as a factor that activated natural killer cells and cytotoxic 
T cells (Stem et aI, 1990). This cytokine strongly favors Th1-type 
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cell-mediated immunity, and T cells are potently activated by 
antigen presentation with the cooperation of CD28/B7 interaction 
and IL-12. 
We utilized the reverse-transcriptase polymerase chain reaction 
to examine levels of mRNA for these three cytokines. CGRP 
augmented the LPS and GM-CSF-induced expression of IL-10 
mRNA in XS52 cells whereas it suppressed the induction of 
mRNA for IL-12 p40 and IL-1� by LPS and GM-CSF in XS52 cells 
and peritoneal macrophages. At the protein level, the LPS and 
GM-CSF-induced production of IL-10 was augrilented by CGRP, 
whereas that of IL-1� was suppressed (Torii et aI, 1997). 
To answer the question as to whether the inhibition of B7-2 
expression by CGRP is mediated by IL-10, the effect of neutralizing 
antibodies to IL-10 on inhibition of B7-2 upregulation was ana­
lyzed by fluorescence-activated cell sorter. Upregulation ofB7-2 
expression by GM-CSF and LPS was suppressed by CGRP in XS52 
cells, as described above. This supression, however, could be 
abrogated by co-culture with neutralizing antibodies to IL-10, 
indicating that the inhibitory effect of CGRP for B7-2 expression 
was, at least in part; mediated by IL-10 (Torii et aI, 1997). 
To examine whether the functional effects ofCGRP on antigen­
presenting function may involve IL-10, preliminary experiments to 
examine the effect of neutralizing antibodies to IL-10 on CGRP 
suppression of epidermal cell antigen-presenting function were 
undertaken. The presence of neutralizing antibodies to IL-10 
during exposure of epidermal cells to CGRP prevented the CGRP­
mediated suppression of epidermal cell presentation of TAA for 
elicitation of DTH in S1509a-immune mice (Torii et aI, 1997). 
These data suggest that suppression of antigen-presenting function 
by CGRP may be mediated, at least in part, by changes in cytokine 
expression that favor less robust antigen presentation for cell­
mediated immunity. 
CONCLUSIONS 
The observation that epidermal Langerhans cells are frequently 
associated anatomically with epidermal nerves and that at least one 
product of those nerves, namely CGRP, can regulate Langerhans 
cell antigen-presenting function suggests the existence of a locus of 
regulatory interaction between the nervous system and the immune 
system in the skin. This hypothesis is attractive because it may, in 
part, explain anecdotal observations that psychologic or neurologic 
status can affect inflammatory skin disease and/or the status of 
cutaneous immunity. At this time, however, there is no evidence 
that �entral nervous system processes can influence reiease or 
non-release of neuropeptides within the skin. Such possibilities are 
the subject of continuing investigation. One mechanism by which 
nerve-derived regulation of immunity in the skin may occur is 
through the axon reflex. Hypothetically, when aliergic inflamma­
tion occurs in the skin, retrograde nerve transmission may occur 
with release of CGRP (and/or other putative active molecules), in 
the vicinity of Langer hans cells where they serve to inhibit antigen 
presentation as a homeostatic mechanism to limit the inflammatory 
response and prevent inappropriate tissue damage. 
The experiments described above indicate that the effect of 
CGRP may be mediated by alterations in cytokiDe expression, 
perhaps most importantly the induction, along with other signals, of 
IL-10. Also, the effects of CGRP ori inhibiting antigen presentation 
varied in potency, depending on the assays examined. Treatment of 
epidermal cells in vitro with CGRP followed by exposure to antigen 
and use for administration in vivo to induce or elicit in vivo immune 
responses leads to profound inhibition of the resporise observed. 
Treatment of epidermal cells with CGRP prior to use for presen­
tation of antigen in wholly in vitro assay systems (presentation of 
alloantigens or immunogenic proteins to responsive hybridomas), 
however, yields only a moderate suppression. The relevance of 
these observations to the in situ effects of CGRP are difficult to 
discern. It may be expected, however, that if CGRP functions as a 
homeostatic mechanism to limit inflammation during immune 
reactions, only moderate inhibition would be anticipated so as to 
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avoid excessive tissue damage while permitting some degree of 
beneficial inflammation to take place. 
The observations discussed within this report raise many ques­
tions. Do other products of nerves regulate Langerhans cell func­
tion? Are functions other than antigen presentation affected by 
products of nerves? In contrast to effects of nerve-derived products 
on Langerhans cells, can Langerhans cells influence nerves by 
release of biologically active agents? These are exciting questions, 
and much work remains to be done before the full panoply of nerve 
Langerhans cell interactions can be understood. 
This work was supported by National [nstilIItes of Health Grant AR42429. 
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